Drug Profile
Cetuximab biosimilar - Dragonboat Biopharmaceutical
Alternative Names: CDP-1Latest Information Update: 01 Jan 2022
Price :
$50
*
At a glance
- Originator Dragonboat Biopharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Colorectal-cancer(In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in China (IV)
- 05 Nov 2019 Dragonboat Biopharmaceutical plans a phase I trial for Solid tumors (Late-stage disease) in China in December 2019 (NCT04151810)
- 27 Feb 2019 Dragonboat Biopharmaceutical Company initiates a phase I trial (In volunteers) in China (NCT03881787)